Takeda Canada currently markets:
- • Actos® (piogliatazone HCI)
- • DEXILANT (dexlansoprazole)
- • Uloric (febuxostat)
Takeda Canada also makes available through its partners the following products: Velcade® (bortezomib), Lupron® (leuprolide acetate), Prevacid® (lansoprazole), and Atacand® (candesartan cilexetil).
Currently, Takeda Canada, Inc. markets oral diabetes, rheumatology and gastroenterology treatments in Canada, and in the future will see further product development for metabolic, cardiovascular, oncology, central nervous system, and other related conditions. Takeda is committed to striving toward better health for patients worldwide through leading innovation in medicine.
The product information on this web site is intended only for residents of Canada.
® Registered trademark owned by Takeda Canada, Inc.
DEXILANT is a trademark of Takeda Pharmaceuticals North America, Inc. and used under license by Takeda Canada, Inc.
ULORIC is a trademark of Teijin Pharma Limited and used under license by Takeda Canada, Inc.